BRISBANE, Calif., Sept. 14 /PRNewswire/ -- SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced that Quinton Oswald has joined the company as Chief Executive Officer.
Mr. Oswald brings significant commercial experience and management expertise to the CEO role. Most recently at Genentech, where he served as the Vice President & Business Unit Head for the Tissue Growth and Repair Business, Mr. Oswald was responsible for four key franchises – Ophthalmology, Growth Hormone, Fibrinolytics and Cystic Fibrosis – generating over $2.1 billion in annual sales. During his tenure at Genentech, Mr. Oswald oversaw the successful commercial launch of Lucentis® (ranibizumab) in 2006, the third fastest new product introduction in U.S. pharma history. Lucentis® was approved for the treatment of neovascular (wet) age-related macular degeneration (AMD) and reached sales of over $1 billion in 2009. This breakthrough therapy dramatically changed the treatment paradigm for retinal specialists by offering their patients the ability to stabilize and improve vision, instead of facing a progressive course toward blindness.
Prior to Genentech, Mr. Oswald led the North American Ophthalmology business for Novartis, which in conjunction with QLT, Inc. pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD. Launched in 2000, Visudyne® replaced thermal laser therapy, offering a more targeted and less damaging treatment to slow vision decline.
"We are very pleased to have Quinton join our team at SARcode," said Robert Alexander, Director at Alta Partners and member of the SARcode Board of Directors. "He brings the right combination of sector knowledge and commercial expertise needed to lead SARcode through Phase III trials and on to the market. Quinton is a perfect fit for this role, given his long